Effect of L-Carnitine Supplementation on Lipid Profiles of Patients with Liver Disease: A Systematic Review and Meta-Analysis.

ABSTRACT

Results of previous studies regarding the effect of L-carnitine on lipid profiles in the patients with liver diseases are contradictory. This meta-analysis was performed to assess the effect of L-carnitine on serum levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG), and total cholesterol (TC) in overweight patients with liver diseases. A systematic search was carried out using the Web of Science, PubMed, Scopus, and Cochrane library databases to identify articles published before April 2019 investigating the effects of L-carnitine supplementation on patients with liver disease. There was no language or time limitation for the studies. A meta-analysis was carried out using both the random and fixed effects model where appropriate, and I2 index were used to evaluate heterogeneity. These results indicated that L-carnitine supplementation significantly reduces blood levels of TC and TG in patients with liver disease, whereas carnitine had no effect on the levels of HDL and LDL. The reducing effect of L-carnitine on both TC and TG was found following long-term carnitine supplementation (≥24 weeks), supplementation with doses less than or equal to 2,000 mg/d, and in patients with chronic hepatitis C. This meta-analysis indicates the beneficial effect of L-carnitine on TC and TG in overweight patients with liver disease, particularly patients with chronic hepatitis C, in both long-term and low doses.